These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23993667)

  • 1. Synthesis and evaluation of novel azetidine analogs as potent inhibitors of vesicular [3H]dopamine uptake.
    Ding D; Nickell JR; Deaciuc AG; Penthala NR; Dwoskin LP; Crooks PA
    Bioorg Med Chem; 2013 Nov; 21(21):6771-7. PubMed ID: 23993667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.
    Nickell JR; Zheng G; Deaciuc AG; Crooks PA; Dwoskin LP
    J Pharmacol Exp Ther; 2011 Mar; 336(3):724-33. PubMed ID: 20876747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2.
    Ding D; Nickell JR; Dwoskin LP; Crooks PA
    Bioorg Med Chem Lett; 2015 Jul; 25(13):2613-6. PubMed ID: 25991431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.
    Nickell JR; Krishnamurthy S; Norrholm S; Deaciuc G; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
    J Pharmacol Exp Ther; 2010 Feb; 332(2):612-21. PubMed ID: 19855096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
    Horton DB; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
    J Pharmacol Exp Ther; 2011 Oct; 339(1):286-97. PubMed ID: 21778282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.
    Nickell JR; Siripurapu KB; Vartak A; Crooks PA; Dwoskin LP
    Adv Pharmacol; 2014; 69():71-106. PubMed ID: 24484975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrrolidine analogs of GZ-793A: synthesis and evaluation as inhibitors of the vesicular monoamine transporter-2 (VMAT2).
    Penthala NR; Ponugoti PR; Nickell JR; Deaciuc AG; Dwoskin LP; Crooks PA
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3342-5. PubMed ID: 23597792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.
    Beckmann JS; Siripurapu KB; Nickell JR; Horton DB; Denehy ED; Vartak A; Crooks PA; Dwoskin LP; Bardo MT
    J Pharmacol Exp Ther; 2010 Dec; 335(3):841-51. PubMed ID: 20805303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2.
    Joolakanti SR; Nickell JR; Janganati V; Zheng G; Dwoskin LP; Crooks PA
    Bioorg Med Chem Lett; 2016 May; 26(10):2422-2427. PubMed ID: 27080180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.
    Horton DB; Nickell JR; Zheng G; Crooks PA; Dwoskin LP
    J Neurochem; 2013 Oct; 127(2):177-86. PubMed ID: 23875622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.
    Miller DK; Crooks PA; Zheng G; Grinevich VP; Norrholm SD; Dwoskin LP
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1035-45. PubMed ID: 15121762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2.
    Nickell JR; Culver JP; Janganati V; Zheng G; Dwoskin LP; Crooks PA
    Bioorg Med Chem Lett; 2016 Jul; 26(13):2997-3000. PubMed ID: 27212067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter.
    Zheng G; Dwoskin LP; Deaciuc AG; Norrholm SD; Crooks PA
    J Med Chem; 2005 Aug; 48(17):5551-60. PubMed ID: 16107155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
    Horton DB; Siripurapu KB; Norrholm SD; Culver JP; Hojahmat M; Beckmann JS; Harrod SB; Deaciuc AG; Bardo MT; Crooks PA; Dwoskin LP
    J Pharmacol Exp Ther; 2011 Mar; 336(3):940-51. PubMed ID: 21177475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders.
    Lee NR; Zheng G; Crooks PA; Bardo MT; Dwoskin LP
    AAPS J; 2018 Feb; 20(2):29. PubMed ID: 29427069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine.
    Lee NR; Zheng G; Leggas M; Janganati V; Nickell JR; Crooks PA; Bardo MT; Dwoskin LP
    J Pharmacol Exp Ther; 2019 Nov; 371(2):526-543. PubMed ID: 31413138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2.
    Nickell JR; Siripurapu KB; Horton DB; Zheng G; Crooks PA; Dwoskin LP
    Eur J Pharmacol; 2017 Jan; 795():143-149. PubMed ID: 27986625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo.
    Meyer AC; Neugebauer NM; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
    J Neurochem; 2013 Oct; 127(2):187-98. PubMed ID: 23875705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine.
    Teng L; Crooks PA; Dwoskin LP
    J Neurochem; 1998 Jul; 71(1):258-65. PubMed ID: 9648873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2).
    Vartak AP; Nickell JR; Chagkutip J; Dwoskin LP; Crooks PA
    J Med Chem; 2009 Dec; 52(23):7878-82. PubMed ID: 19691331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.